BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35681071)

  • 21. Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype.
    Aghi M; Kluwe L; Webster MT; Jacoby LB; Barker FG; Ojemann RG; Mautner VF; MacCollin M
    J Neurosurg; 2006 Feb; 104(2):201-7. PubMed ID: 16509493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
    Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
    J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2).
    Zhao Y; Kumar RA; Baser ME; Evans DG; Wallace A; Kluwe L; Mautner VF; Parry DM; Rouleau GA; Joe H; Friedman JM
    Genet Epidemiol; 2002 Oct; 23(3):245-59. PubMed ID: 12384977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe phenotype of neurofibromatosis type 2 in a patient with a 7.4-MB constitutional deletion on chromosome 22: possible localization of a neurofibromatosis type 2 modifier gene?
    Bruder CE; Ichimura K; Blennow E; Ikeuchi T; Yamaguchi T; Yuasa Y; Collins VP; Dumanski JP
    Genes Chromosomes Cancer; 1999 Jun; 25(2):184-90. PubMed ID: 10338003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.
    Baser ME; Kuramoto L; Woods R; Joe H; Friedman JM; Wallace AJ; Ramsden RT; Olschwang S; Bijlsma E; Kalamarides M; Papi L; Kato R; Carroll J; Lázaro C; Joncourt F; Parry DM; Rouleau GA; Evans DG
    J Med Genet; 2005 Jul; 42(7):540-6. PubMed ID: 15994874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
    Sun S; Liu A
    J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2.
    Baser ME; Makariou EV; Parry DM
    J Neurosurg; 2002 Feb; 96(2):217-22. PubMed ID: 11838793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical manifestations and genetic analysis of a family with neurofibromatosis type 2.
    Wang VY; Liu TY; Fang TY; Chen YH; Huang CJ; Wang PC
    Acta Otolaryngol; 2022 Jan; 142(1):36-42. PubMed ID: 34915804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatic neurofibromatosis type 2 gene mutations and growth characteristics in vestibular schwannoma.
    Irving RM; Harada T; Moffat DA; Hardy DG; Whittaker JL; Xuereb JH; Maher ER
    Am J Otol; 1997 Nov; 18(6):754-60. PubMed ID: 9391673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset.
    Smith MJ; Higgs JE; Bowers NL; Halliday D; Paterson J; Gillespie J; Huson SM; Freeman SR; Lloyd S; Rutherford SA; King AT; Wallace AJ; Ramsden RT; Evans DG
    J Med Genet; 2011 Apr; 48(4):261-5. PubMed ID: 21278391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing.
    Evans DG; Hartley CL; Smith PT; King AT; Bowers NL; Tobi S; Wallace AJ; Perry M; Anup R; Lloyd SKW; Rutherford SA; Hammerbeck-Ward C; Pathmanaban ON; Stapleton E; Freeman SR; Kellett M; Halliday D; Parry A; Gair JJ; Axon P; Laitt R; Thomas O; Afridi SK; Obholzer R; ; Duff C; Stivaros SM; Vassallo G; Harkness EF; Smith MJ
    Genet Med; 2020 Jan; 22(1):53-59. PubMed ID: 31273341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular Biological Background of Neurofibromatosis Type 2].
    Miyawaki S; Teranishi Y; Saito N
    No Shinkei Geka; 2022 May; 50(3):572-577. PubMed ID: 35670170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of induced pluripotent stem cell clones derived from a patient with mosaic neurofibromatosis type 2.
    Ishi Y; Era T; Yuzawa S; Okamoto M; Sawaya R; Motegi H; Yamaguchi S; Terasaka S; Houkin K; Fujimura M
    Am J Med Genet A; 2022 Jun; 188(6):1863-1867. PubMed ID: 35178855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas.
    Mohyuddin A; Neary WJ; Wallace A; Wu CL; Purcell S; Reid H; Ramsden RT; Read A; Black G; Evans DG
    J Med Genet; 2002 May; 39(5):315-22. PubMed ID: 12011146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease.
    Ruttledge MH; Andermann AA; Phelan CM; Claudio JO; Han FY; Chretien N; Rangaratnam S; MacCollin M; Short P; Parry D; Michels V; Riccardi VM; Weksberg R; Kitamura K; Bradburn JM; Hall BD; Propping P; Rouleau GA
    Am J Hum Genet; 1996 Aug; 59(2):331-42. PubMed ID: 8755919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presenting symptoms in children with neurofibromatosis type 2.
    Gugel I; Grimm F; Teuber C; Zipfel J; Tatagiba M; Mautner VF; Schuhmann MU; Kluwe L
    Childs Nerv Syst; 2020 Oct; 36(10):2463-2470. PubMed ID: 32537663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype.
    Patronas NJ; Courcoutsakis N; Bromley CM; Katzman GL; MacCollin M; Parry DM
    Radiology; 2001 Feb; 218(2):434-42. PubMed ID: 11161159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes.
    Kluwe L; Bayer S; Baser ME; Hazim W; Haase W; Fünsterer C; Mautner VF
    Hum Genet; 1996 Nov; 98(5):534-8. PubMed ID: 8882871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurofibromatosis type 2 (NF2): diagnosis and management.
    Lloyd SK; Evans DG
    Handb Clin Neurol; 2013; 115():957-67. PubMed ID: 23931824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.
    Kehrer-Sawatzki H; Kluwe L; Friedrich RE; Summerer A; Schäfer E; Wahlländer U; Matthies C; Gugel I; Farschtschi S; Hagel C; Cooper DN; Mautner VF
    Hum Genet; 2018 Jul; 137(6-7):543-552. PubMed ID: 30006736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.